Company / R&D Expense
Sana Biotechnology, Inc. R&D Expense History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$217.6M
FY2024
5-year range
$132.9M / $285.9M
FY2020-FY2024
Trend
-19.1%
vs FY2023
Sector context
#78 of 210
Health Care
What the data says
At $218M, Sana Biotechnology, Inc.'s r&d expense ranks #78 of 210 in the Health Care sector. Declined from $286M to $218M over the past 2 years.
Based on SEC 10-K filings.
$218M in FY2024 with a 5-year CAGR of +16.9%.
Declined from $286M to $218M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -4.4%
- 5-Year CAGR
- +16.9%
- 10-Year CAGR
- -
Sector benchmark
#78 of 210 in Health CareTop 37% of 210This company $217.6M Sector average $644.1M
▼
-66.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +16.9%, indicating consistent growth.
- In FY2024, r&d expense decreased 19.1% year-over-year.
- Ranks #78 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $217.6M | -19.1% |
| FY2023 | $268.8M | -6.0% |
| FY2022 | $285.9M | +15.0% |
| FY2021 | $248.6M | +87.0% |
| FY2020 | $132.9M | +33.5% |
| FY2019 | $99.6M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026